KZIA KAZIA THERAPEUTICS LTD IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1075880 · Reporting currency AUD · Fiscal year ends 06/30
Financial factors as of 2018-06-30 (FY2018), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: AUD | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 | FY20212021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 42,000 | 2.31M | 0 | 0 | 15.18M |
| R&D expense | 7.33M | 17.38M | 15.56M | 20.17M | 14.54M |
| SG&A expense | 8.72M | 13.56M | 8.58M | 5.11M | 7.02M |
| Pretax income | -22.45M | -27.05M | -20.74M | -25.38M | -8.90M |
| Income tax | -1.75M | -271,000 | -271,000 | -368,000 | -484,000 |
| Net income | -20.70M | -26.78M | -20.46M | -25.01M | -8.42M |
| EPS (basic) | -0.04 | -0.10 | -0.11 | -0.19 | -0.07 |
| EPS (diluted) | -0.04 | -0.10 | -0.11 | -0.19 | -0.07 |
| Weighted avg. shares (diluted) | 547.94M | 263.68M | 184.28M | 132.47M | 117.67M |
| Balance sheet | |||||
| Cash & equivalents | 4.34M | 1.66M | 5.24M | 7.36M | 27.59M |
| Receivables | 97,911 | 3.90M | 3.90M | 91,000 | 84,000 |
| Current assets | 4.93M | 6.14M | 10.77M | 9.45M | 29.39M |
| Intangibles | 1.09M | 15.40M | 17.27M | 19.14M | 21.01M |
| Total assets | 6.06M | 21.59M | 28.08M | 35.89M | 58.09M |
| Current liabilities | 14.05M | 25.80M | 7.57M | 6.73M | 8.33M |
| Short-term debt | 395,640 | 634,000 | 1.80M | 1.84M | — |
| Total liabilities | 14.36M | 31.60M | 16.03M | 17.61M | 20.24M |
| Shareholders' equity | -8.30M | -10.02M | 12.05M | 18.27M | 37.85M |
| Cash flow statement | |||||
| Operating cash flow | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M |
| Investing cash flow | — | 0 | 0 | -2.37M | — |
| Financing cash flow | 15.98M | 5.99M | 12.97M | 3.73M | 28.11M |
| Depreciation & amortization | — | — | 1.87M | 1.87M | 1.26M |
| Stock-based compensation | 653,000 | 533,000 | 1.16M | 1.68M | 637,000 |
| Dividends paid | 0 | 0 | 0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.